| thiamine |
drug |
5 |
2 |
vitamin B, vitamin B1 |
| thiamine deficiency |
drug |
5 |
5 |
enzyme deficiency preventing thiamine use, thiamine-deficiency, thiamine-deficient state |
| thiamine pyrophosphate |
drug |
2 |
— |
TPP |
| thiazolidinediones |
drug |
4 |
4 |
PPARγ agonists, TZDs |
| thiazovivin |
drug |
2 |
1 |
ROCK inhibitor, Rock inhibitor, thiasovivin |
| thickness |
phenotype |
4 |
2 |
cortical thickness |
| thioflavin-S |
drug |
2 |
2 |
Thioflavin S |
| Thionin |
drug |
4 |
4 |
Thionin dye |
| THIP |
drug |
3 |
2 |
4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol, Gaboxadol, gaboxadol |
| thought problems |
phenotype |
3 |
1 |
|
| threat-related amygdala reactivity |
phenotype |
2 |
— |
|
| THSD7B |
gene |
3 |
2 |
Thrombospondin Type 1 Domain Containing 7B |
| thyroid cancer |
phenotype |
4 |
1 |
|
| Thyroid hormones |
drug |
2 |
2 |
|
| TIC Genetics |
cohort |
2 |
1 |
TIC Genetics trios |
| tics |
phenotype |
8 |
4 |
CTDs, chronic tic disorder, chronic/persistent tic disorders, tic disorder |
| tic severity |
phenotype |
2 |
2 |
Yale Global Tic Severity Scale Total Tic Score, lifetime tic severity, severity of tics, worst-ever tic severity |
| time |
phenotype |
4 |
2 |
time post-consumption |
| Time Spent |
phenotype |
2 |
2 |
|
| Time spent drinking |
phenotype |
3 |
2 |
time spent, time spent drinking |
